Orion Biotech Opportunities Corp. Warrant
ORIAW
ORIAW was delisted on the 28th of April, 2023.
30 hedge funds and large institutions have $2.63M invested in Orion Biotech Opportunities Corp. Warrant in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
15% more funds holding
Funds holding: 26 → 30 (+4)
34% less capital invested
Capital invested by funds: $3.95M → $2.63M (-$1.33M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$72.2K |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$51.6K |
| 3 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$51.6K |
| 4 |
CAC
Cowen and Company
New York
|
+$13.7K |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
+$10.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$28K |
| 2 |
FIG
Fortress Investment Group
New York
|
-$13.8K |
| 3 |
DCM
DG Capital Management
New York
|
-$4.88K |
| 4 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$4.48K |
| 5 |
FLC
Fifth Lane Capital
Austin,
Texas
|
-$4K |
ORIAW Hedge Fund Activity: Q1 2022 in Review
30 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Warrant (ORIAW) for Q1 2022, worth a combined $2.63M — down 34% from $3.95M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ORIAW positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Linden Advisors, opening a new position worth an estimated $72.2K. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $28K sold.
- 30 institutional investors held Orion Biotech Opportunities Corp. Warrant (ORIAW) as of Q1 2022, up from 26 in Q4 2021.
- Funds reported $2.63M of Orion Biotech Opportunities Corp. Warrant stock for Q1 2022, down 34% quarter-over-quarter.
- 6 funds opened new Orion Biotech Opportunities Corp. Warrant positions in Q1 2022 and 2 closed out, a net change of +4 holders.
- The largest Orion Biotech Opportunities Corp. Warrant buyer in Q1 2022 was Linden Advisors, an estimated $72.2K added.
- The largest Orion Biotech Opportunities Corp. Warrant seller in Q1 2022 was Picton Mahoney Asset Management, an estimated $28K sold.
Based on aggregated 13F filings for Q1 2022.